Repirinast

Repirinast (MY-5116) is an orally active anti-allergic agent. Repirinast inhibits histamine release. Repirinast can be used in the research of bronchial asthma.

Repirinast inhibits histamine release from rat peritoneal mast cells induced by antigen (IC₅₀: 0.3 μM)^[3].

Repirinast (30 mg/kg, i.p.) inhibits antigen-induced early and late pulmonary responses in guinea pigs^[1].
Repirinast (30 mg/kg, p.o.) inhibits antigen-induced immediate bronchoconstriction in rats^[2].

References:
[1]. N Yamada, et al. Repirinast inhibits antigen-induced early and late pulmonary responses and airway hyperresponsiveness in guinea pigs. Int Arch Allergy Immunol. 1993;100(4):367-72.
[2]. Takahashi K. Effects of MY-5116 on experimental asthma in rats and guinea pigs. Arerugi. 1986 Oct; 35(10): 1037-46.
[3]. M Takei, et al. Inhibition of histamine release from rat peritoneal mast cells by MY-1250, an active metabolite of Repirinast (MY-5116). Int Arch Allergy Appl Immunol. 1990;93(2-3):237-41.